All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-17T09:24:36.000Z

EHA 2019 | Could the first-in-class anti-CD47 antibody HU5F9-G4 be a promising treatment strategy?

By Emily Smith, David Sallman
Featured
David Sallman
Jun 17, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), David Sallman from the Moffitt Cancer Center, Tampa, US, discusses if the first-in-class anti-CD47 antibody HU5F9-G4 (5F9) could be a promising treatment strategy for patients with acute myeloid leukemia (AML).
 
5F9 is a first-in-class IgG4 antibody that targets CD47 to enable phagocytosis. David Sallman discusses the initial results from the phase Ib trial investigating 5F9 alone, or with azacitidine, in patients with high-risk AML and myelodysplastic syndrome (MDS). The early data indicate that 5F9 is well-tolerated, with promising activity in patients with AML/MDS, and that adding 5F9 to cytotoxic agents may be a promising treatment strategy.

Could the first-in-class anti-CD47 antibody HU5F9-G4 be a promising treatment strategy?

More about...
Antibody therapyEHA 2019

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
13 votes - 3 days left ...

Related articles

Add bookmark

Can CD47 antibody therapy be safely used for AML and MDS?

Podcast discussion between David Sallman, Moffitt Cancer Center, and Naval Daver, MD Anderson Cancer Center, held during the 25th Congress of theEHA. The AML Hub asked: Is CD47-directed...

Jun 22, 2020
Add bookmark

Can CD47 antibody therapy be safely used for AML and MDS?

Podcast discussion between David Sallman, Moffitt Cancer Center, and Naval Daver, MD Anderson Cancer Center, held during the 25th Congress of...

Jun 22, 2020
Add bookmark

David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML

David Sallman talks about results from the THINK trial, a phase I study assessing the safety and clinical activity of multiple CYAD‑01 administrations...

Dec 18, 2018
Add bookmark

David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML

David Sallman talks about results from the THINK trial, a phase I study assessing the safety and...

Dec 18, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox